Assays measuring PD-L1 expression on tumor cells has been approved by US Food and Drug Administration as a companion diagnostic for PD-1/PD-L1 blockade therapy to determine whether a patient can benefit from the therapy17. The gene discussed is CD274; the disease is neoplasm.